Berlin - Delayed Quote EUR

Daiichi Sankyo Co Ltd (D4S.BE)

Compare

26.62

+0.28

+(1.06%)

As of 8:09:58 AM GMT+1. Market Open.

No Tool

Measure

UNDO

Redo

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for D4S.BE

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Daiichi Sankyo Co Ltd (D4S.BE)

Comparisons

Indicators

Technicals

Corporate Events

-1.66%

0.64%

-8.30%

-20.75%

2.27%

0.11%

28.81%

519.07%

Recent News: D4S.BE

FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients

DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m

Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH

Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC

AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn

Daiichi Sankyo doses first subject in Phase III AML therapy trial

AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC

QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML